Deep Track Capital
200 Greenwich Ave., 3rd Floor, Greenwich, CT, 06830, United States
Overview
Investment firm focused on life sciences and biotech industry.
Founded
2020
Deals ยท 12mo
13
Links
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Superluminal Medicines | Sep 2026Participated | $60 MSeries B | |
Mentari Therapeutics | Jul 2026Participated | $200 MOther Equity | |
Draig Therapeutics | Jul 2026Led | $65 MSeries B | |
Oblenio Bio | Jun 2026Participated | $62 MSeries B | |
Triveni Bio | Jun 2026Participated | $65 MSeries C | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
Mentari Therapeutics | May 2026Participated | $290 MOther Equity | |
Terremoto Biosciences | Apr 2026Participated | $108 MSeries C | |
Ambrosia Biosciences | Mar 2026Led | $100 MSeries B | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Century Therapeutics | Jan 2026Participated | $135 MOther Equity | |
Hemab | Oct 2025Participated | $157 MSeries C | |
Superluminal Medicines | Sep 2026Participated | $60 MSeries B | |
Mentari Therapeutics | Jul 2026Participated | $200 MOther Equity | |
Draig Therapeutics | Jul 2026Led | $65 MSeries B | |
Oblenio Bio | Jun 2026Participated | $62 MSeries B | |
Triveni Bio | Jun 2026Participated | $65 MSeries C | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
Mentari Therapeutics | May 2026Participated | $290 MOther Equity | |
Terremoto Biosciences | Apr 2026Participated | $108 MSeries C | |
Ambrosia Biosciences | Mar 2026Led | $100 MSeries B | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Century Therapeutics | Jan 2026Participated | $135 MOther Equity | |
Hemab | Oct 2025Participated | $157 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 2 |
| Series B | 7 | 19 |
| Series C+ | 4 | 11 |
| Other Equity | 2 | 7 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 2 |
| Aug '21 | 3 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 1 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 2 |
| Jun '23 | 1 |
| Jul '23 | 1 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 2 |
| Apr '24 | 4 |
| May '24 | 1 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 3 |
| Sep '24 | 0 |
| Oct '24 | 2 |
| Nov '24 | 1 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 1 |
| Apr '25 | 2 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 2 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 2 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 2 |
| Jun '26 | 2 |
| Jul '26 | 2 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 53 |
| AI & Machine Learning | 2 |
| Space & Frontier Tech | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 1 |
| $50M-$100M | 18 |
| $100M-$250M | 29 |
| $250M-$500M | 3 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 46 |
| Europe | 7 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 25 |
| Janus Henderson Investors | 15 |
| Frazier Life Sciences | 11 |
| Venrock | 10 |
| RTW Investments | 9 |
| Surveyor Capital | 9 |
| Logos Capital | 8 |
| Atlas Venture | 7 |
| Cormorant Asset Management | 6 |
| Driehaus Capital Management | 6 |
| Invus | 6 |
| Novo Holdings | 6 |
| OrbiMed | 6 |
| Samsara BioCapital | 6 |
| TCGX | 6 |
| Access Biotechnology | 5 |
| Bristol Myers Squibb | 5 |
| BVF Partners | 5 |
| Fairmount | 5 |
| Goldman Sachs | 5 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 14 | 26% |
| Participating | 39 | 74% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 7 | 50% |
| Co-led | 7 | 50% |
Team
Founder & Chief Investment Officer
Business Development and Strategy
Principal